Teva (TEVA) calls active after patent board says certain claims of Copaxone patent invalid
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Teva Pharma (NYSE: TEVA) August 55 and 57.50 calls are active on total call volume of 25K contracts (15K puts) after the U.S. Patent and Trademark Office's Patent Trial and Appeal Board, or PTAB, determined that Mylan Pharmaceuticals (MYL) and Amneal Pharmaceuticals, as co-petitioners, met their "burden of proving the unpatentability of claims 1-20 of '250 patent by a preponderance of the evidence." August call option implied volatility is at 47, September is at 38; compared to its 52-week range of 16 to 49.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CenturyLink (CTL) options swept up on WSJ report of advanced merger talks with Level 3 (LVLT)
- UPDATE: KKR & Co. (KKR) said to be investor in Netscout Systems (NTCT)
- Altria (MO) weekly option implied volatility increases to 25 into Q3
Create E-mail Alert Related CategoriesOptions, Trader Talk
Related EntitiesOptions, myl
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!